Sign in
SYRE Stock Price, Chart, Stats & News
Spyre Therapeutics, Inc.
Save
6.06B
Market cap
–
Current P/E
–
Forward P/E
SYRE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | -231.58% |
Pretax margin | -171.52% |
Net margin | -171.51% |
Effective tax rate | 0.01% |
ROA | -19.95% |
ROE | -29.44% |
D/E | – |
Interest coverage ratio | – |
SYRE valuation
P/E | – |
P/S | 31.58x |
P/B | 22.89x |
P/CF | -96.73x |
P/FCF | -16.88x |
P/OCF | -96.73x |
PEG | 2.01x |
EV multiple | -16.42x |
About
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD.
Similar securities
Based on sector and market capitalization
Report issue